Shristae Therapeutics is a Philadelphia-based biotechnology company developing biotherapeutics to address the fundamental drivers of vascular-immune and neurodegenerative dysfunction. Founded by Dr. Das, Shristae integrates deep biological insight with operational precision to build first-in-class therapeutic and diagnostic solutions.

Dr. Das is also the founder of One Biotech Solutions (DBA: OBS, TYSPAR LLC), a specialized QC company serving the cell and gene therapy ecosystem. This dual perspective strengthens Shristae’s translational strategy while maintaining full separation between the two companies.

Shristae Therapeutics is dedicated to treating immune-vascular conditions by targeting the molecular origins of disease. We are pioneering the next generation of therapies for immune-vascular conditions. Through our expertise in siRNA and antibody development, we target specific molecular pathways to restore vascular health and resolve systemic inflammation. We don’t just treat symptoms; we reprogram the biological response. Our platform leverages two powerful, complementary modalities:

🧬siRNA Therapeutics: To knock down intracellular drivers of vascular/ inflammation that were previously considered “undruggable.”

🧬Monoclonal Antibodies: To provide high-affinity extracellular modulation of key immune-vascular receptors.

By focusing on targets with proven amenability to these dual platforms, we accelerate the journey from target identification to clinical impact.